%0 Journal Article
%A Guberina, Maja
%A Metzenmacher, Martin
%A Pöttgen, Christoph
%A Wiesweg, Marcel
%A Guberina, Nika
%A Merkel-Jens, Anja
%A Lütke-Brintrup, Diana
%A Bölükbas, Servet
%A Eberhardt, Wilfried E E
%A Stamatis, Georgios
%A Doerr, Fabian
%A Plönes, Till
%A Hoffmann, Christian
%A Zaun, Gregor
%A Höing, Benedikt
%A Kürten, Cornelius
%A Mladenov, Emil
%A Iliakis, George
%A Kersting, David
%A Fendler, Wolfgang P
%A Gauler, Thomas
%A Opitz, Marcel
%A Milosevic, Aleksandar
%A Forsting, Michael
%A Nensa, Felix
%A Umutlu, Lale
%A Funke, Faustina
%A Hautzel, Hubertus
%A Herrmann, Ken
%A Taube, Christian
%A Theegarten, Dirk
%A Aigner, Clemens
%A Schuler, Martin
%A Stuschke, Martin
%T Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer.
%J Thoracic cancer
%V 16
%N 22
%@ 1759-7706
%C Hoboken, NJ ˜[u.a.]œ
%I Wiley-Blackwell
%M DKFZ-2025-02569
%P e70183
%D 2025
%X To analyze the association of pathologic-complete-response (PCR) and survival after neoadjuvant concurrent chemo-radiotherapy, we evaluated a large cohort of patients with potentially resectable stage IIIA-IIIC non-small cell lung cancer (NSCLC) treated with a trimodality approach.Consecutive patients underwent neoadjuvant induction chemotherapy, followed by concurrent chemo-radiotherapy and surgery. Patients received established imaging, and diagnostics. Leave-one-out cross-validation was employed to identify the most effective prognostic classifier.Altogether, 403 patients treated between 06/2000 and 01/2020 were included. Median follow-up was 111 months (IQR: 71-127 months). PCR was achieved in 34
%K Humans
%K Carcinoma, Non-Small-Cell Lung: pathology
%K Carcinoma, Non-Small-Cell Lung: mortality
%K Carcinoma, Non-Small-Cell Lung: therapy
%K Carcinoma, Non-Small-Cell Lung: drug therapy
%K Male
%K Female
%K Neoadjuvant Therapy: methods
%K Neoadjuvant Therapy: mortality
%K Lung Neoplasms: pathology
%K Lung Neoplasms: mortality
%K Lung Neoplasms: therapy
%K Lung Neoplasms: drug therapy
%K Induction Chemotherapy: methods
%K Middle Aged
%K Aged
%K Neoplasm Staging
%K Prognosis
%K Chemoradiotherapy: methods
%K Pathologic Complete Response
%K induction chemo‐radiotherapy (Other)
%K major pathological response (Other)
%K pathologic complete response (Other)
%K potentially resectable stage III NSCLC (Other)
%K predictor of survival (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41261778
%R 10.1111/1759-7714.70183
%U https://inrepo02.dkfz.de/record/306357